IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Product Class Date Terms of Agreement
Foradil Aerolizer
(formoterol fumarate)
Zaditen (ketotifen
fumarate)
Focalin
(dexmethylphenidate)
Estraderm MX/Estraderm
TTS (17 beta estradiol)
Famvir (famciclovir) and
Vectavir/Denavir
(penciclovir)
Stalevo (entacapone +
levodopa + carbidopa)
Exelon (rivastigmine) N 1999-
2005
L 2002 Schering-Plough acquired US marketing & distribution
rights for an upfront payment, milestones & royalties.
N/C/R 2002 Canadian rights licensed to PanGeo Pharma.
N 2000 Novartis licensed-in rights from Celgene for development
and commercialization worldwide, outside Canada.
G 2000 Japanese marketing transferred to Kissei.
J 2000 Licensed-in from GlaxoSmithKline for worldwide markets.
N 2000 Co-promotion and co-marketing deal with Orion.
Originally licensed-in from Orion in 1998.
In 2005, Novartis and Ono agreed to co-develop and
co-market the rivastigmine transdermal patch in Japan.
Rivastigmine was licensed-out to Esteve for co-marketing
in Spain in 1999 by Novartis. Exteva co-markets it in
Spain as Prometax.
Diovan (valsartan) C 1999 Schwarz acquired co-marketing rights in Germany.
Menarini co-markets in Italy. Novartis and Choong-Wae
have a co-promotion agreement for South Korea.
Vivelle (17 beta estradiol
patch)
G 1999 Novartis acquired rights in Europe and certain other
countries. In 1998, Novartis and Noven established a jv,
Vivelle Ventures (became Novogyne Pharmaceuticals in
1999), to market Vivelle in North America. Originally
licensed out by Noven to Ciba for marketing in North
America in 1991.
Visudyne (verteporfin) S 1995 Verteporfin was discovered at the University of British
Columbia and was co-developed by QLT
PhotoTherapeutics and CIBA Vision. The University of
British Colombia licensed verteporfin to QLT, which
sublicensed it to CIBA Vision for worldwide
co-development and co-marketing. The deal was
expanded in 2000.
Femara (letrozole) L 1994 Novartis and Chugai agreed to co-market in Japan.
© 2009 IMS Health In cor po rated or its af fil i ates Page 125